{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:39:57Z","timestamp":1793756397418,"version":"4.6.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T00:00:00Z","timestamp":1551830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T00:00:00Z","timestamp":1551830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Imiquimod (IMQ)-induced skin inflammation is currently the most widely accepted psoriasis animal model, however, it features several limitations. We have modified the IMQ-model to minimize its systemic effects towards effectively maintaining the characteristic skin reactions. The original protocol (OP) uses 62.5\u2009mg Aldara cream (or vaseline) on the shaved back skin of mice for 4 days. In contrast, in our modified protocol (MP) 25\u2009mg Aldara and vaseline are applied simultaneously in separate Finn chambers over the dorsal skin of mice. In both the OP and MP groups, histology showed unequivocal hallmarks of psoriasiform dermatitis. Additionally, skin scaling and blood perfusion values were similar. While Aldara elicited significantly increased skin thickness in the MP group, significant weight loss, spleen enlargement, increased inflammatory cytokine levels in plasma, and treatment related death were only observed in the OP group. Our new method reproduces psoriatic skin alterations highlighting considerably reduced systemic inflammatory reactions. Possessing psoriasiform and control skin areas on the same mouse also reduces inter-individual differences. Additionally, the new method permits prolonged IMQ treatment studies to mimic the chronic nature of psoriasis. Finally, our experimental approach may also be used in other mouse models, to prevent the undesired systemic effects of topically applied drugs.<\/jats:p>","DOI":"10.1038\/s41598-019-39903-x","type":"journal-article","created":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T11:07:05Z","timestamp":1551870425000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Methodological refinement of Aldara-induced psoriasiform dermatitis model in mice"],"prefix":"10.1038","volume":"9","author":[{"given":"Szabina","family":"Horv\u00e1th","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Koml\u00f3di","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anik\u00f3","family":"Perkecz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Pint\u00e9r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolland","family":"Gyulai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4523-3938","authenticated-orcid":false,"given":"\u00c1gnes","family":"Kem\u00e9ny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,6]]},"reference":[{"key":"39903_CR1","doi-asserted-by":"publisher","first-page":"5836","DOI":"10.4049\/jimmunol.0802999","volume":"182","author":"L van der Fits","year":"2009","unstructured":"van der Fits, L. et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23\/IL-17 axis. J. Immunol. 182, 5836\u20135845 (2009).","journal-title":"J. Immunol."},{"key":"39903_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-017-0415-3","volume":"9","author":"WR Swindell","year":"2017","unstructured":"Swindell, W. R. et al. Imiquimod has strain-dependent effects in mice and does not uniquely model human psoriasis. Genome Med. 9, 24 (2017).","journal-title":"Genome Med."},{"key":"39903_CR3","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1038\/jid.2014.98","volume":"134","author":"R Yoshiki","year":"2014","unstructured":"Yoshiki, R. et al. IL-23 from Langerhans Cells Is Required for the Development of Imiquimod-Induced Psoriasis-Like Dermatitis by Induction of IL-17A-Producing \u03b3\u03b4 T Cells. J. Invest. Dermatol. 134, 1912\u201321 (2014).","journal-title":"J. Invest. Dermatol."},{"key":"39903_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms2566","volume":"4","author":"A Walter","year":"2013","unstructured":"Walter, A. et al. Aldara activates TLR7-independent immune defence. Nat. Commun. 4, 1560 (2013).","journal-title":"Nat. Commun."},{"key":"39903_CR5","doi-asserted-by":"publisher","unstructured":"Kem\u00e9ny, \u00c1. et al. TRPA1 acts in a protective manner in imiquimod-induced psoriasiform dermatitis in mice. J. Invest. Dermatol. https:\/\/doi.org\/10.1016\/j.jid.2018.02.040 (2018).","DOI":"10.1016\/j.jid.2018.02.040"},{"key":"39903_CR6","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/ni.2585","volume":"14","author":"EE Gray","year":"2013","unstructured":"Gray, E. E. et al. Deficiency in IL-17-committed V\u03b34\u2009+\u2009\u03b3\u03b4 T cells in a spontaneous Sox13-mutant CD45.1+ congenic mouse substrain provides protection from dermatitis. Nat. Immunol. 14, 584\u2013592 (2013).","journal-title":"Nat. Immunol."},{"key":"39903_CR7","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.jid.2016.10.024","volume":"137","author":"JE Hawkes","year":"2017","unstructured":"Hawkes, J. E., Gudjonsson, J. E. & Ward, N. L. The Snowballing Literature on Imiquimod-Induced Skin Inflammation in Mice: A Critical Appraisal. J. Invest. Dermatol. 137, 546\u2013549 (2017).","journal-title":"J. Invest. Dermatol."},{"key":"39903_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/srep20134","volume":"6","author":"L Grine","year":"2016","unstructured":"Grine, L. et al. Topical imiquimod yields systemic effects due to unintended oral uptake. Sci. Rep. 6, 20134 (2016).","journal-title":"Sci. Rep."},{"key":"39903_CR9","first-page":"1","volume":"9","author":"HR Kim","year":"2014","unstructured":"Kim, H. R. et al. Reactive oxygen species prevent imiquimod-induced psoriatic dermatitis through enhancing regulatory T cell function. PLoS One 9, 1\u201314 (2014).","journal-title":"PLoS One"},{"key":"39903_CR10","doi-asserted-by":"publisher","unstructured":"Vinter, H. et al. TNF\u03b1 plays a significant role in the Aldara-induced skin inflammation in mice. Br. J. Dermatol. n\/a-n\/a https:\/\/doi.org\/10.1111\/bjd.14320 (2015).","DOI":"10.1111\/bjd.14320"},{"key":"39903_CR11","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1016\/j.ajpath.2018.02.005","volume":"188","author":"M Madsen","year":"2018","unstructured":"Madsen, M. et al. Imiquimod-Induced Psoriasis-Like Skin Lesions Do Not Accelerate Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient Mice. Am. J. Pathol. 188, 1486\u20131496 (2018).","journal-title":"Am. J. Pathol."},{"key":"39903_CR12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejphar.2018.01.048","volume":"824","author":"Y-H Kuang","year":"2018","unstructured":"Kuang, Y.-H. et al. Topical Sunitinib ointment alleviates Psoriasis-like inflammation by inhibiting the proliferation and apoptosis of keratinocytes. Eur. J. Pharmacol. 824, 57\u201363 (2018).","journal-title":"Eur. J. Pharmacol."},{"key":"39903_CR13","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.jss.2008.05.002","volume":"153","author":"MC Cheung","year":"2009","unstructured":"Cheung, M. C. et al. Body Surface Area Prediction in Normal, Hypermuscular, and Obese Mice. J. Surg. Res. 153, 326\u2013331 (2009).","journal-title":"J. Surg. Res."},{"key":"39903_CR14","doi-asserted-by":"publisher","first-page":"42.e1","DOI":"10.1016\/j.ajog.2011.06.105","volume":"206","author":"DR Pachman","year":"2012","unstructured":"Pachman, D. R. et al. Randomized clinical trial of imiquimod: an adjunct to treating cervical dysplasia. Am. J. Obstet. Gynecol. 206, 42.e1\u20137 (2012).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"39903_CR15","doi-asserted-by":"publisher","first-page":"6748","DOI":"10.1158\/1078-0432.CCR-12-1149","volume":"18","author":"S Adams","year":"2012","unstructured":"Adams, S. et al. Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer. Clin. Cancer Res. 18, 6748\u201357 (2012).","journal-title":"Clin. Cancer Res."},{"key":"39903_CR16","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.aad1329","volume":"350","author":"M Vetizou","year":"2015","unstructured":"Vetizou, M. et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350, 1079\u20131084 (2015).","journal-title":"Science"},{"key":"39903_CR17","doi-asserted-by":"publisher","first-page":"e0159539","DOI":"10.1371\/journal.pone.0159539","volume":"11","author":"Z Zakostelska","year":"2016","unstructured":"Zakostelska, Z. et al. Intestinal Microbiota Promotes Psoriasis-Like Skin Inflammation by Enhancing Th17 Response. PLoS One 11, e0159539 (2016).","journal-title":"PLoS One"},{"key":"39903_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9424","volume":"6","author":"P Zanvit","year":"2015","unstructured":"Zanvit, P. et al. Antibiotics in neonatal life increase murine susceptibility to experimental psoriasis. Nat. Commun. 6, 8424 (2015).","journal-title":"Nat. Commun."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-39903-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-39903-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-39903-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T07:07:09Z","timestamp":1671260829000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-39903-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,6]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["39903"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-39903-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,6]]},"assertion":[{"value":"29 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"3685"}}